Inozyme Pharma, Inc. (INZY)
NASDAQ: INZY · Real-Time Price · USD
1.000
0.00 (0.03%)
Mar 14, 2025, 11:33 AM EDT - Market open

Inozyme Pharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2018
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2018
Net Income
-102.02-71.17-67.06-56.62-56.42
Upgrade
Depreciation & Amortization
0.740.830.740.670.22
Upgrade
Loss (Gain) From Sale of Assets
-0.020.02--
Upgrade
Asset Writedown & Restructuring Costs
----17.76
Upgrade
Loss (Gain) From Sale of Investments
-5.04-5.44-1.670.170.28
Upgrade
Stock-Based Compensation
7.957.047.677.162.31
Upgrade
Other Operating Activities
1.761.120.530.38-
Upgrade
Change in Accounts Payable
1.36-1.380.15-0.682.1
Upgrade
Change in Other Net Operating Assets
3.35-1.71.860.76-2.21
Upgrade
Operating Cash Flow
-91.91-70.68-57.76-48.15-35.97
Upgrade
Capital Expenditures
-0.06-0.3-0.41-0.4-0.57
Upgrade
Investment in Securities
67.06-53.35-4.9943.19-116.61
Upgrade
Investing Cash Flow
67-53.65-5.442.8-117.18
Upgrade
Long-Term Debt Issued
-404.05--
Upgrade
Net Debt Issued (Repaid)
-404.05--
Upgrade
Issuance of Common Stock
11.485.9768.740.61116.17
Upgrade
Financing Cash Flow
11.4125.9772.790.61149.81
Upgrade
Foreign Exchange Rate Adjustments
0-0.02-0.030.02-
Upgrade
Net Cash Flow
-13.511.639.6-4.72-3.34
Upgrade
Free Cash Flow
-91.97-70.97-58.17-48.55-36.54
Upgrade
Free Cash Flow Per Share
-1.46-1.37-1.54-2.06-3.31
Upgrade
Cash Interest Paid
4.352.350.17--
Upgrade
Levered Free Cash Flow
-55.09-46.05-32.07-27.29-29.91
Upgrade
Unlevered Free Cash Flow
-51.61-43.96-31.9-27.29-29.91
Upgrade
Change in Net Working Capital
-4.784.26-3.01-0.67-3.78
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.